QuickView for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=9A293F9B4FD554D3CFAA1B9898B171E8;jsessionid=C8B5755C1AB667BEC9CC28337B057DA7;jsessionid=2EF4DCA6033AFE03CF0EE436C968A892;jsessionid=530CEE8B325EFD03D3A53D720DD64EB8;jsessionid=D97779AA5DC7CD54724A7CA5A45154BF;jsessionid=024FBC8EF10B57A2124BF746581BD867;jsessionid=F930074A3D0B3D280E0AAB258D32C939 (gene)

1. Thymic stroma and TFII-I: towards new targeted therapies.
2. Proteomic analysis of SRF associated transcription complexes identified TFII-I as modulator of SRF f…
3. Structural basis for evolutionarily conserved interactions between TFIIS and Paf1C.
4. The TFIIS N-terminal domain (TND): a transcription assembly module at the interface of order and dis…
5. Astragaloside IV attenuates sunitinib-associated cardiotoxicity by inhibiting COUP-TFII.

There were no clinical trials for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=9A293F9B4FD554D3CFAA1B9898B171E8;jsessionid=C8B5755C1AB667BEC9CC28337B057DA7;jsessionid=2EF4DCA6033AFE03CF0EE436C968A892;jsessionid=530CEE8B325EFD03D3A53D720DD64EB8;jsessionid=D97779AA5DC7CD54724A7CA5A45154BF;jsessionid=024FBC8EF10B57A2124BF746581BD867;jsessionid=F930074A3D0B3D280E0AAB258D32C939